Literature DB >> 3604581

Giant axonal neuropathy. A neuropathological study.

H A Kretzschmar, B O Berg, R L Davis.   

Abstract

Giant axonal neuropathy (GAN) is a disease characterized by a slowly progressive neuropathy and signs of central involvement, manifested by visual impairment, corticospinal tract dysfunction, ataxia, and dementia. Pathological hallmarks of the disease include axonal swellings packed with neurofilaments in both peripheral and central nervous systems, and accumulations of intermediate filaments in Schwann cells, fibroblasts, melanocytes, endothelial, and Langerhans cells. Rosenthal fibers, sometimes appearing in masses and mimicking Alexander's disease, emerge as a conspicuous characteristic in longstanding GAN.

Entities:  

Mesh:

Year:  1987        PMID: 3604581     DOI: 10.1007/bf00693779

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  36 in total

1.  Giant axonal neuropathy: a childhood disorder of microfilaments.

Authors:  T Koch; P Schultz; R Williams; P Lampert
Journal:  Ann Neurol       Date:  1977-05       Impact factor: 10.422

2.  Infantile chronic peripheral neuropathy with giant axons. Report of a case.

Authors:  H Jedrzejowska; H Drac
Journal:  Acta Neuropathol       Date:  1977-03-31       Impact factor: 17.088

3.  Neurofibrillary tangles induced by vincristine and vinblastine sulfate in central and peripheral neurons in vitro.

Authors:  F J Seil
Journal:  Exp Neurol       Date:  1968-06       Impact factor: 5.330

4.  Giant axonal neuropathy: an inborn error of organization of intermediate filaments.

Authors:  S D Pena
Journal:  Muscle Nerve       Date:  1982-02       Impact factor: 3.217

5.  Giant axonal neuropathy: normal protein composition of neurofilaments.

Authors:  V Ionasescu; C Searby; P Rubenstein; A Sandra; P Cancilla; J Robillard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-06       Impact factor: 10.154

6.  Giant axonal neuropathy. Endocrinological and histological studies.

Authors:  A Fois; P Balestri; M A Farnetani; R Berardi; R Mattei; E Laurenzi; C Alessandrini; R Gerli; A Ribuffo; S Calvieri
Journal:  Eur J Pediatr       Date:  1985-09       Impact factor: 3.183

7.  A study of glial fibrillary acidic protein (GFAP) in childhood brain tumours.

Authors:  H B Marsden; S Kumar; J Kahn; B J Anderton
Journal:  Int J Cancer       Date:  1983-04-15       Impact factor: 7.396

8.  Glial fibrillary acidic protein in human gliomas.

Authors:  J D van der Meulen; H J Houthoff; E J Ebels
Journal:  Neuropathol Appl Neurobiol       Date:  1978 May-Jun       Impact factor: 8.090

9.  Mitosis and intermediate-sized filaments in developing skeletal muscle.

Authors:  H Ishikawa; R Bischoff; H Holtzer
Journal:  J Cell Biol       Date:  1968-09       Impact factor: 10.539

10.  The role of three cytoplasmic fibers in BHK-21 cell motility. I. Microtubules and the effects of colchicine.

Authors:  R D Goldman
Journal:  J Cell Biol       Date:  1971-12       Impact factor: 10.539

View more
  13 in total

1.  Giant axonal neuropathy: report on a case with focal fiber loss.

Authors:  M Sabatelli; E Bertini; S Servidei; E Fernandez; S Magi; P Tonali
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Giant axonal neuropathy alters the structure of keratin intermediate filaments in human hair.

Authors:  Asfia Soomro; Richard J Alsop; Atsuko Negishi; Laurent Kreplak; Douglas Fudge; Edward R Kuczmarski; Robert D Goldman; Maikel C Rheinstädter
Journal:  J R Soc Interface       Date:  2017-04       Impact factor: 4.118

3.  Demyelination and axonal dystrophy in alpha A-crystallin transgenic mice.

Authors:  E P De Rijk; A F Van Rijk; E Van Esch; W W De Jong; P Wesseling; H Bloemendal
Journal:  Int J Exp Pathol       Date:  2000-08       Impact factor: 1.925

4.  Giant axonal neuropathy: observations on a further patient.

Authors:  M Donaghy; E M Brett; I E Ormerod; R H King; P K Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

5.  Giant axonal neuropathy: clinical and genetic study in six cases.

Authors:  E Demir; P Bomont; S Erdem; L Cavalier; M Demirci; G Kose; S Muftuoglu; A N Cakar; E Tan; S Aysun; M Topcu; P Guicheney; M Koenig; H Topaloglu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

6.  Giant axonal neuropathy (GAN): an immunohistochemical and ultrastructural study report of a Latin American case.

Authors:  A L Taratuto; G Sevlever; M Saccoliti; L Caceres; M Schultz
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

7.  Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Authors:  Saleemulla Mahammad; S N Prasanna Murthy; Alessandro Didonna; Boris Grin; Eitan Israeli; Rodolphe Perrot; Pascale Bomont; Jean-Pierre Julien; Edward Kuczmarski; Puneet Opal; Robert D Goldman
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

8.  3T MR with diffusion tensor imaging and single-voxel spectroscopy in giant axonal neuropathy.

Authors:  Christiana Brenner; Carlos Eduardo Speck-Martins; Luciano Farage; Peter B Barker
Journal:  J Magn Reson Imaging       Date:  2008-07       Impact factor: 4.813

Review 9.  Dysfunctions of neuronal and glial intermediate filaments in disease.

Authors:  Ronald K H Liem; Albee Messing
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

10.  Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy.

Authors:  Eitan Israeli; Dilyan I Dryanovski; Paul T Schumacker; Navdeep S Chandel; Jeffrey D Singer; Jean P Julien; Robert D Goldman; Puneet Opal
Journal:  Hum Mol Genet       Date:  2016-03-21       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.